130198-71-9

Upstream product

• 2067-33-6 5-bromopentanoic acid 
• 100-02-7 4-nitro-phenol 
• 5454-83-1 5-bromovaleric acid methyl ester 

Downstream Products

• 103797-32-6 5-(4-nitrophenoxy)pentanoic acid 
• 130031-47-9 Acridin-9-yl-(4-{4-[bis-(2-chloro-ethyl)-amino]-phenoxy}-butyl)-amine 
• 130198-75-3 5-{4-[Bis-(2-hydroxy-ethyl)-amino]-phenoxy}-pentanoic acid methyl ester 
• 857479-99-3 5-{4-[Bis-(2-chloro-ethyl)-amino]-phenoxy}-pentanoic acid methyl ester 
• 130198-82-2 [4-(4-Amino-butoxy)-phenyl]-bis-(2-chloro-ethyl)-amine 
• 92700-02-2 5-{4-[bis-(2-chloro-ethyl)-amino]-phenoxy}-valeric acid 
• 130198-74-2 5-(4-amino-phenoxy)-valeric acid methyl ester 

Relevant academic research and scientific papers

The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase

A novel class of podophyllotoxin derivatives have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors. Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated. The aromatic capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed. Among all of the synthesized hybrid compounds, compound 24d showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level. Further exploration of this series led to the discovery of potent dual inhibitor 32, which exhibited the strongest in vitro cytotoxic activity.